

20, AVENUE APPIA - CH-1211 GENEVA 27 - SWITZERLAND - TEL CENTRAL +41 22 791 2111 - FAX CENTRAL +41 22 791 3111 - WWW.WHO.INT

Tel. direct: +41 22 791 3927 Premier Medical Corporation Private

Fax direct: +41 22 791 4836 Limited E-mail:

diagnostics@who.int Attention: Dr Rajeshkumar G. Sheliya

Director

In reply please refer to: DH/vl A1-302, GIDC

Sarigam, District, Valsad Your reference: P17-370-9

396155

Inde

17 March 2021

Dear Dr Sheliya,

Subject: WHO Emergency Use Listing (EUL) - Product eligible for listing

Product name: Sure Status COVID-19 Antigen Card Test

Application number: EUL 0590-010-00

Product codes: SS03P25

Regulatory version: Rest of world

We are pleased to inform you that the above-referenced product was listed as eligible for WHO procurement on 17 March 2021. The EUL listing can be leveraged by other international, regional and national procurement agencies. The product will be eligible for procurement for 1 year, unless circumstances dictate otherwise.

Please be advised that the on-going eligibility status of the above-referenced product depends on fulfilling the commitments to EUL listing identified in the "Dossier review complete" letter sent 17 March 2021.

The following activities are required to maintain the eligibility status:

- 1. Notification to WHO of any planned changes to the above-referenced product, in accordance with "WHO procedure for changes to a WHO prequalified in vitro diagnostic" (document number PQDx 121); and
- 2. Post-market surveillance activities, in accordance with "Guidance for post-market surveillance and market surveillance of medical devices, including in vitro diagnostics" (ISBN 978-92-4-001531-9).

Failure to comply with any of the above-mentioned requirements may lead to remedial action by WHO, including but not limited to, de-listing from the WHO EUL procedure list of eligible in vitro diagnostics products.

The draft public report will be sent to you in the coming days for review. The final public report with an outcome of the review, any commitments to EUL listing, instructions for use and labelling will be published on our website.

If you have any questions, please do not hesitate to contact us by email (diagnostics@who.int) or by telephone (+4122 791 3927).

Yours sincerely,

Mr Deus Mubangizi

Unit Head

Prequalification Unit

Regulation and Prequalification Department

Access to Medicines and Health Products Division